In a welcome move for access to medicines, the Delhi High Court has rejected the appeal filed by...Bayer Corporation against an earlier court order which had rejected the implementation of a drug regulatory system which essentially linked registration of medicines to their patent status... “We are delighted with this decision – at the moment in India we are seeing a number of multinational pharmaceutical companies trying to use litigation to stifle generic competition,” said Dr. Tido von Schoen-Angerer of Médecins Sans Frontières’ Campaign for Access to Essential Medicines. “By rejecting Bayer’s attempts to introduce patent linkage, the Indian courts have ensured that public health safeguards like compulsory licensing can be used to open up generic production of life-saving medicines including antiretrovirals for millions in India and beyond..." [also refers to Novartis]